Caris Life Sciences (CAI) Gross Margin (2024 - 2026)

Caris Life Sciences' Gross Margin history runs 3 years deep, the most recent figure standing at 99.1% for Q1 2026.

• On a quarterly basis, Gross Margin rose 4946.0% year-over-year to 99.1% in Q1 2026; TTM through Mar 2026 was 57.14%, a 1589.0% decrease from a year earlier, with the FY2025 full-year figure at 67.69%, down 2978.0% from the prior year.
• Gross Margin climbed to 99.1% in Q1 2026 per CAI's latest filing, from 13.05% in the prior quarter.
• Across five years, Gross Margin topped out at 99.1% in Q1 2026 and bottomed at 13.05% in Q4 2025.
• The 3-year median for Gross Margin is 66.55% (2025), against an average of 66.92%.
• Across the five-year window, Gross Margin slumped 8443 bps in 2025 and jumped 4946 bps in 2026, its largest moves.
• Year by year, Gross Margin stood at 97.48% in 2024, then sank by 87 bps to 13.05% in 2025, then soared by 659 bps to 99.1% in 2026.
• Per Business Quant, the three latest CAI Gross Margin figures stand at 99.1% (Q1 2026), 13.05% (Q4 2025), and 69.11% (Q3 2025).